BROADWOOD CAPITAL INC - Q3 2018 holdings

$1.08 Billion is the total value of BROADWOOD CAPITAL INC's 9 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .

 Value Shares↓ Weighting
STAA  STAAR SURGICAL CO$521,049,000
+54.8%
10,855,1790.0%48.40%
+25.3%
MNST  MONSTER BEVERAGE CORP NEW$278,212,000
+1.7%
4,773,7080.0%25.84%
-17.7%
IWM  ISHARES TRrussell 2000 etf$70,791,000
+2.9%
420,0000.0%6.58%
-16.7%
BTX  BIOTIME INC$70,433,000
+14.1%
29,971,5610.0%6.54%
-7.7%
AXON  AXON ENTERPRISE INC$52,011,000
+8.3%
760,0620.0%4.83%
-12.4%
MNST  MONSTER BEVERAGE CORP NEWput$46,624,000
+1.7%
800,0000.0%4.33%
-17.7%
OCX  ONCOCYTE CORPORATION$18,912,000
-2.0%
7,564,9340.0%1.76%
-20.7%
DAL  DELTA AIR LINES INC DELput$11,566,000
+16.7%
200,0000.0%1.07%
-5.6%
AST  ASTERIAS BIOTHERAPEUTICS INC$6,880,000
-3.7%
5,292,1560.0%0.64%
-22.1%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STAAR SURGICAL CO42Q3 202359.1%
MONSTER BEVERAGE CORP NEW34Q3 202349.7%
ISHARES TR33Q3 202314.8%
ONCOCYTE CORPORATION31Q2 20234.6%
BIOTIME INC25Q2 201917.8%
AXON ENTERPRISE INC24Q3 202313.4%
AGEX THERAPEUTICS INC20Q3 20231.5%
LINEAGE CELL THERAPEUTICS INC17Q3 20235.1%
ASTERIAS BIOTHERAPEUTICS INC16Q4 20182.9%
CYNOSURE INC15Q4 201610.4%

View BROADWOOD CAPITAL INC's complete holdings history.

Latest filings
TypeFiled
42024-04-15
13F-HR2024-02-14
42024-02-08
42024-01-10
42024-01-05
42023-11-30
13F-HR2023-11-14
42023-11-14
42023-11-09
42023-11-06

View BROADWOOD CAPITAL INC's complete filings history.

Compare quarters

Export BROADWOOD CAPITAL INC's holdings